Navin Fluorine International Limited (NAVINFLUOR) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Navin Fluorine International Limited is a specialty chemicals company built on fluorine chemistry, spanning High-Performance Products (including refrigerants), Specialty Chemicals and CDMO services, and it enters the Q2 FY 2026-2027 print on the back of a Q1 that grew revenue 44% YoY with a 34.2% operating EBITDA margin. The quarter's swing factors are raw-material inflation — fluorspar and sulfur prices firmed through July-August after HF prices already cost ~100 bps of gross margin in Q1 — and whether margins hold above management's 30% full-year EBITDA guidance band.

Navin Fluorine International Limited Q2 Results Date and Time

Navin Fluorine is scheduled to report its Q2 FY 2026-2027 results on October 30, 2026.

What to expect from Navin Fluorine International Limited's Q2 FY27 results

The Q2 FY27 print will test whether Navin Fluorine's margins can stay above the FY27 guidance anchor of 30% (plus/minus 1-2%) that management reaffirmed on the August 5 Q1 call, after Q1 FY27 ran at 34.2%. Input costs are the quarter's swing factor: fluorspar firmed through the window (China FOB USD 530.55/MT in August 2026 vs USD 512.63 in July), sulfur spiked to about USD 1,050/t (+275% YoY) before easing late in September, and HF prices had already dipped Q1 gross margin ~100 bps QoQ. Offsetting supports include quota-backed refrigerant realizations — R32 industry quota utilization stood at 96.71% as of October 14, with R125 and R32 gaining more than 60% cumulatively in the six months to end-June 2026 — and a rupee that traded around 95-96.6/USD through September versus about 94.3 pre-quarter, a realizations tailwind for an export-led book. On growth, the first full-quarter contribution from the Chemours project (completed end June/early July 2026), the CDMO ramp toward the $100 million aspiration after 82% Q1 YoY growth, and India AC sales growing double-digit in July-September point to another strong YoY revenue print, though LatAm agchem pricing pressure persisted through the window with no recovery in the retrieved evidence. The call will also be watched for confirmation that the R32/HFC capacity (up to 15,000 MTPA) and MPP debottlenecking remain on track for Q3 FY27 commissioning, the point at which management has flagged projects transition from investment phase to revenue generation.

Key Things To Watch

Guidance scorecard: margin anchor and FY27 targets: Q1 FY27 started well above the full-year band, so the key question is whether management holds, re-bases or flags H2 dilution.

• FY27 EBITDA margin — 30% ±1-2% (full-year), also framed as 32-33% ±1% with operating leverage — versus Q1 FY27 at 34.2%; check whether the 30% anchor is re-based
• FY27 revenue growth — double-digit guided — versus Q1 FY27 growth of 44% YoY; check H2 risk factors
• Capacity utilization — guided from 50-60% to 70-75% in FY27 — track quarterly progression
• Employee costs — guided at ~7-8% of revenue — against Q1 FY27 employee expenses of Rs. 86.57 Cr on Rs. 1,045.08 Cr revenue

R32/HFC and MPP commissioning timeline: Both projects are due within the current quarter of the call.

• R32/HFC capacity (up to 15,000 MTPA, Rs. 236.5 Cr capex) and MPP debottlenecking at Dahej (Rs. 75 Cr) — commissioning by Q3 FY27; confirm timing and ramp
• HFC offtake — a couple of contracts entered and a couple more in final stages; ask whether they were signed and how the open-position strategy over the next five years evolves
• Chemours project — completed end June/early July 2026; seek ramp-up and revenue contribution commentary from the first full quarter

Raw material pass-through and gross margin: Sulfur, fluorspar and HF inflation is the dominant cost overhang management has flagged.

• Q1 FY27 gross margin dipped ~100 bps QoQ on rising HF prices; ask about the pricing lag and Q2 gross margin
• Management has expressed confidence in passing on raw material inflation to customers, with pricing calibrated to input-cost moves and an acknowledged lag effect

CDMO and Advanced Materials milestones: Multiple project checkpoints fall due across FY27.

• cGMP4 Phase II — Rs. 125 Cr capex, completion by Q4 FY27 — progress check
• Advanced Materials adoption capacity — Rs. 90 Cr, completion by Q2 FY28 — progress on five lab-approved products
• Fermion commercial supplies ramping from the dedicated cGMP4 block, with the $5 billion peak sales projection by 2028/2029 as publicly disclosed by partners Orion and Bayer; CDMO $100 million aspiration after 82% Q1 YoY growth

Specialty chemicals tone on LatAm pricing: Pricing pressure has been the persistent drag on this segment.

• LatAm agchem pricing pressure described as persistent, with the market 'already well supplied'; watch for any change in tone alongside 48% Q1 FY27 Specialty revenue growth
• Specialty margins — management has guided no return to historical 30% EBITDA margins (open-ended)